Clinical trials: Mild Hypertension
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension, Dyslipidemia
Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension
This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.
- Trial name
- NCT03267329
- Testing
- Duowell®, Telmisartan
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Hypertension
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach…
- Trial name
- NCT02969265
- Testing
- Amlodipine, TCV-116CCB
- Where
- 25 sites in China
- Sponsor
- Takeda
Hypertension
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood pressure lowering effects of oral doses of…
- Trial name
- NCT00424541
- Testing
- SPP100 (aliskiren)
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Novartis
Hypertension
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use…
- Trial name
- NCT00638911
- Volunteers
- 33,247 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
A study to compare the effects of Diovan or Atenolol taken for 12 weeks on platelet function of patients who have mild to moderately severe hypertension
- Trial name
- NCT00171756
- Testing
- valsartan/atenolol
- Where
- Switzerland
- Volunteers
- 92 people
- Sponsor
- Novartis
Chronic Kidney Disease, Hypertension
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
- Trial name
- NCT05491642
- Testing
- BAY3283142
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 56 people
- Sponsor
- Bayer
Hypertension
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
- Trial name
- KARDIA-1 (NCT04936035)
- Testing
- ALN-AGT01
- Where
- 75 sites in United States, Canada and 3 more
- Volunteers
- 394 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
- Trial name
- NCT00273052
- Testing
- Carvedilol Phosphate modified release formulation, metoprolol succinate
- Where
- 120 sites in United States, Canada and 1 more
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Open-angle Glaucoma, Cataract
Efficacy and Safety of Trabecular Meshwork Microstent Drainage System ( MicroCOGO )
It is a prospective, multicenter, randomized, open label, parallel controlled, superiority clinical trial that evaluate efficacy and safety of Trabecular Meshwork Microstent Drainage System in Reducing Intraocular Pressure in…
- Trial name
- MicroCOGO (NCT06741774)
- Testing
- Trabecular Meshwork Microstent Drainage System, phacoemulsification
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Healthguard Biomed
Hypertension
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic…
- Trial name
- NCT00171054
- Testing
- Valsartan 320 mg, Amlodipine 10 mg, Hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 125 people
- Sponsor
- Novartis
Essential Hypertension
Essential Hypertension
The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.
- Trial name
- REDUCE-1 (NCT01264692)
- Testing
- ACT-280778, Amlodipine
- Where
- 18 sites in Israel, Serbia
- Volunteers
- 196 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG).
- Trial name
- NCT01670266
- Testing
- ONO-9054
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ono Pharma USA Inc
Essential,Hypertension
Fimasartan Achieving SBP Target (FAST) Study
The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension.
- Trial name
- FAST (NCT02495324)
- Testing
- Fimasartan, Valsartan, Olmesartan medoxomil
- Where
- 8 sites in South Korea
- Volunteers
- 369 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
AVE7688 in Patients With Mild to Moderate Blood Pressure
The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12.
- Trial name
- RAVEL-1 (NCT00284128)
- Testing
- AVE7688, Losartan-potassium
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 1,940 people
- Sponsor
- Sanofi
Hypertension
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
- Trial name
- NCT06236061
- Testing
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg
- Where
- 43 sites in Japan
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension,Essential
Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects.
- Trial name
- NCT06501586
- Testing
- SGB-3908
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.